Physician profile
Joseph E Chadwick
NPI 1801887674
$3,737.39
in general payments reported to CMS, 2019-2025
33 companies · $45.67 in 2025
The $45.67 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,316 · 2020: $996 · 2021: $430 · 2022: $327 · 2023: $471 · 2024: $151 · 2025: $45.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $668.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $668.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $546.09 | 2019-2023 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $518.53 | 2019-2023 | Trelegy Ellipta |
| Lilly USA, LLC | $304.97 | 2019-2023 | Jardiance, Trulicity, Mounjaro |
| Janssen Pharmaceuticals, INC | $289.67 | 2019-2022 | |
| Amgen INC. | $241.35 | 2019-2025 | Evenity, Prolia |
| Abbott Laboratories | $199.06 | 2022-2024 | Freestyle Libre 3 |
| Pfizer INC. | $188.53 | 2019-2023 | |
| Radius Health, INC. | $156.21 | 2019 | |
| Amarin Pharma, INC. | $155.46 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.52 | 2019-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $116.49 | 2019-2024 | Farxiga |
| Novartis Pharmaceuticals Corporation | $111.71 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $83.54 | 2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $75.18 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $73.67 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akcea Therapeutics, INC. | $49.19 | 2020 | |
| Abbvie INC. | $46.12 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.11 | 2019 | |
| Avanir Pharmaceuticals, INC. | $43.14 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $40.89 | 2019-2020 | |
| Eisai INC. | $40.17 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $39.81 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.77 | 2023 | |
| Genentech USA, INC. | $34.06 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.26 | 2021-2024 | Trintellix |
| Allergan, INC. | $29.24 | 2019-2020 | |
| Boston Scientific Corporation | $18.70 | 2022 | |
| Esperion Therapeutics, INC. | $18.00 | 2020 | |
| Shield Therapeutics INC | $15.58 | 2023 | Accrufer |
| Otsuka America Pharmaceutical, INC. | $15.41 | 2025 | Rexulti |
| Sumitomo Pharma America, INC. | $14.81 | 2023 | Aptiom |
| E.R. Squibb & Sons, L.L.C. | $14.06 | 2023 | |
| Medtronic USA, INC. | $12.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Chadwick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.